Israeli experimental COVID drug cured 30 out of 30 COVID-19 cases in the first clinical trial.
Despite already having one of the most successful vaccine rollout plans, Israel is already working on new COVID relief options.
Israel is currently testing out two drugs via clinical trials that are showing a triumphant return. The drug doses are named EXO-CD25 and Allocetra.
Allocetra is an immunotherapy drug that is currently in Phase II of its clinical trial with COVID-19 patients.
In October, five COVID-19 intensive care COVID patients were discharged from medical centers in Israel with the treatment of this revolutionary medicine.
On the other hand, EXO-CD24 is an inhaled medication developed in Tel Aviv, and it cured 30 out of 30 moderate to severe cases.
“29 of whom the medical condition improved within two to three days and most of them were discharged home within three to five days. The 30th patient also recovered but after a longer time,” Tel Aviv Sourasky Medical Center.
“The drug is based on exosomes, [vesicles] that are released from the cell membrane and used for intercellular communication. We enrich the exosomes with 24CD protein. This protein is expressed on the surface of the cell and has a known and important role in regulating the immune system,” Dr. Shiran Shapira, who is a veteran researcher of the 24CD protein.
“The preparation is given by inhalation, once a day, for only a few minutes, for five days,” Shapira said.
These new experimental drugs could be a game-changer in how Israel handles the vaccine and the rest of the world.
If both medications do pass clinical trials, COVID-19 patients could have an array of options when it comes to beating the virus.
There is still a long way to go for medical options that battle COVID-19, but this is yet another sign of the potential end to COVID’s attack on the globe.